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1. Introduction 
Adenosine is a ubiquitous nucleoside that acts as a neuromodulator in the central nervous 
system (CNS), controlling neuronal excitability, modulating neurotransmitter release, and 
regulating ion channel function through four subtypes of G-protein-coupled receptors 
(GPCRs), A1, A2A, A2B, and A3. Adenosine receptor agonists are anxiolytic while adenosine 
A1 and A2A receptor antagonists such as caffeine can cause anxiety.  Pharmacological and 
genetic manipulation of A1 and A2A receptors suggests that each contributes separately to 
the regulation of anxious states. However, a growing body of evidence argues for a 
particularly important role of the A2A receptor. Single nucleotide polymorphisms (SNPs) in 
the A2A receptor gene (ADORA2A) are associated with anxiety in psychiatric disorders and 
in response to stimulants. Additionally, genetic knockout of the type 1 equilibrative 
nucleoside transporter (ENT1), which plays an essential role in controlling adenosine levels 
in the brain, reduces anxiety in rodents, while inhibition of ENT1 may mediate the 
anxiolytic effects of benzodiazepines and alcohol. In this chapter, we discuss the emerging 
role of adenosine signaling in anxiety, with special focus on the A1 and A2A receptors and 
ENT1. This chapter also includes how caffeine and alcohol regulate anxiety through 
adenosine signaling. 
2. Adenosine in the CNS 
Adenosine has several roles in the CNS that are critical to proper brain function. As a 
nucleoside, adenosine is the precursor to adenine nucleotides in DNA and RNA. It can also be 
phosphorylated to produce ATP, the main form of cellular metabolic energy. Conversely, it is 
a product of ATP hydrolysis and as such, represents an indicator of metabolic activity. As a 
neuromodulator, adenosine can inhibit or excite neurons based upon physiological conditions 
at the time. Thus, adenosine signaling is best conceptualized as a gating mechanism for 
signaling by other neurotransmitters, modulating both excitatory and inhibitory 
neurotransmission. It is in this capacity that adenosine regulates a wide range of behaviors, 
moods, and emotions (Cunha et al., 2008; Ruby et al., 2010; Asatryan et al., 2011). 
Because adenosinergic signaling impacts most neurotransmitter systems in the brain, 
extracellular adenosine levels must be tightly regulated to support proper neuronal 
function. Unlike classical neurotransmitters that are synthesized, stored, and released into 
the synapse in response to electrochemical stimulation, adenosine concentrations are 
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regulated to a much greater extent by production and transport (Burnstock, 1972, 2006, 
2008). This pattern of control allows adenosine levels to change rapidly, which is essential to 
fine-tune the activity of neighboring neurons. Adenosine reaches extracellular space in two 
ways: 1) it is produced extracellularly from ATP released by neurons or by astrocytes, and 2) 
it is released through equilibrative nucleoside transporters (ENTs; Fig. 1). Interestingly, 
astrocytes appear to be significant sources of extracellular adenosine and ATP (Haydon et 
al., 2009). 
 
 
Fig. 1. Schematic showing adenosine production in the central nervous system. 
Abbreviations: cNT: cytosolic endo-nucleotidase, AK: adenosine kinase, ENT, equilibrative 
nucleoside transporters, eNT: exo-nucleotidase, ADA: adenosine deaminase, A1R and A2AR: 
adeonsine A1 and A2A receptors. 
Adenosine controls neurotransmitter release, modulates neuronal excitability and regulates 
ion channel function through four subtypes of GPCRs, A1, A2A, A2B, and A3, all with distinct 
affinity for adenosine. Whether adenosine exerts a dampening or potentiating effect on 
neurotrasmission is determined by the expression pattern of adenosine receptors and the 
levels of adenosine in the brain (Fredholm et al., 1999; Fredholm et al., 2005b; Fredholm et al., 
2005a; Fredholm, 2010). A1 and A2A receptors have 10-100 nM binding affinities, whereas A2B 
and A3 receptors have 1-5 mM binding affinities. Since normal CNS adenosine levels are 25-
250 nM, A1 and A2A receptors are the main subtypes involved in the regulation of anxiety and 
other psychiatric disorders. Adenosine A1 receptors are expressed ubiquitously in the CNS, 
have high affinity for adenosine, and mediate tonic inhibition of neuronal activity. Activation 
of presynaptic A1 receptors inhibits the release of excitatory and inhibitory neurotransmitters 
by reducing intracellular cAMP and PKA activation, while postsynaptic A1 receptors regulate 
potassium channels to reduce both excitability (the probability of firing) as well as action 
potential duration (Ebersolt et al., 1983; Fredholm, 1985; Linden, 1991; Heurteaux et al., 1995). 
Adenosine A2A receptors are primarily expressed in the caudate-putamen and nucleus 
accumbens. In contrast to A1 receptors, A2A receptors are positively linked to adenylate 
cyclase, increasing levels of cAMP and exerting excitatory influences on neurons. A2A 
receptors are also known to associate physically with other neurotransmitter receptors, 
including the dopamine D2 and glutamate mGluR5 receptors. Such receptor-receptor 
interactions appear to be essential for striatal function, and evidence suggests that they may be 
impaired in a number of psychiatric diseases (Ferre et al., 2010).  
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3. Adenosine receptors and transporters in anxiety 
Adenosine and adenosine receptor agonists are anxiolytic as assessed by a number of 
ethological tests in rodent models, such as the elevated zero maze and elevated plus maze 
(Kulkarni et al., 2007), the Vogel conflict test (Okuyama et al., 1999), and the light-dark (LD) 
box (Florio et al., 1998). Conversely, adenosine receptor antagonism is responsible for the 
anxiogenic responses elicited by moderate to high doses of caffeine, theophylline (Imaizumi 
et al., 1994; Kulkarni et al., 2007; Pechlivanova et al., 2010), or other adenosine receptor 
antagonists (Imaizumi et al., 1994; Florio et al., 1998; Koetter et al., 2009; Zhao et al., 2009) in 
rodents and humans (Lara, 2010). It has also been suggested that the anxiolytic effect of the 
adenine derivative BWA78U in the LD box involves adenosine receptor activation (Willard 
et al., 1990), and that adenosine is the active principle in the Longan Arillus extract 
(Okuyama et al., 1999), a traditional Asian remedy for mild anxiety. Moreover, adenosine 
may mediate, in part, the anxiolytic activity of benzodiazepine receptor ligands (Snell and 
Snell, 1984; Stone, 1999). Genetic evidence supports roles for the A1 and A2A receptors, as 
well as the transporter ENT1 in the regulation of anxious states.    
3.1 The A2A receptor 
Of the many studies implicating adenosine signaling in emotional behavior, the strongest 
evidence favors a central role for the A2A receptor subtype in anxiety-related disorders 
under many different conditions (Shen and Chen, 2009). The A2A receptor is enriched in the 
caudate-putamen and nucleus accumbens, where it interacts physically with dopamine D2 
receptors to regulate reward, habitual behavior, and locomotor activity (Cunha et al., 2008). 
As the A2A receptor is expressed in both neurons and astrocytes, it has also been implicated 
in controlling glial function and brain metabolic adaptation, processes that are dysregulated 
in several psychiatric disorders (Lee et al., 2007; Rajkowska and Miguel-Hidalgo, 2007).   
Persuasive preclinical evidence for the involvement of the A2A receptor in anxiety comes 
from several studies based on its genetic deletion combined with pharmacological 
manipulation. Indeed, A2A receptor null mice are considered a valuable model to study 
anxiety disorders and develop new therapies (Deckert, 1998). These mice display reduced 
exploratory activity, heightened anxiety and aggression, hypoalgesia, increased blood 
pressure and heart rate, and aberrant locomotor responses to caffeine (Ledent et al., 1997), 
including caffeine-induced depression (rather than enhancement) of exploration (Ledent et 
al., 1997), and the absence of an anxiogenic response to acute or chronic high-dose caffeine 
in the elevated plus maze (El Yacoubi et al., 2000). This evidence is in line with a 
pharmacological study showing that the adenosine A2 receptor agonist CGS21680 reduced 
the anxiogenic effect of theophylline in the LD box (Imaizumi et al., 1994). Surprisingly, 
however, A2A receptor overexpression did not alter anxiety-like responses in the elevated 
plus maze (Gimenez-Llort et al., 2007).  
Pharmacological and genetic inhibition of the A2A receptor has also revealed its role in the 
regulation of anxiety in disease states, by other neuromodulators, or by drugs of abuse. One 
study showed increased content of a-MSH, a pro-opiomelanocortin (POMC)-derived 
peptide known to influence anxiety, aggressive behavior, and motor activity, in the 
amygdala and cortex of A2A receptor knockouts (Jegou et al., 2003). The mice also had 
augmented levels of POMC mRNA and ACTH in the anterior pituitary, indicating 
hyperactivity of the hypothalamic-pituitary-adrenal axis that mediates responses to stress 
(Jegou et al., 2003). The A2A receptor has also been implicated in the anxiolytic activity of 
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prostaglandin D2, as A2A receptor inhibition by SCH58261 prevented the increase in open-
arm time produced by prostaglandin D2 in the elevated plus maze. In addition, A2A receptor 
blockade prior to quinolinic acid-induced striatal excitotoxic lesions (a rat model of 
Huntington’s disease), prevented the usual increase in anxiety-like behavior for 6 months 
(Scattoni et al., 2007).  Moreover, the A2A receptor may be involved in anxiety during 
morphine withdrawal, as A2A receptor null mice display more severe naloxone-precipitated 
withdrawal symptoms (Berrendero et al., 2003). Finally, these mice are more sensitive to the 
anxiolytic properties of alcohol (Houchi et al., 2008). These studies and other research 
implicating adenosine signaling in the effects of alcohol are discussed later in the chapter. 
 
Disorders SNPs References 
Panic Disorder 
1083C>T 
Hamilton et al., 2004 
1976C>T 
rs5751876 Hohoff et al., 2010 
Agoraphobia 
1083C>T Hamilton et al., 2004 
rs5751876 Hohoff et al., 2010 
Blood-Injury Phobia 1976C>T Hohoff et al., 2009 
Autism Spectrum Disorder 
rs2236624CC 
Freitag et al., 2010 
rs3761422 
rs5751876 
rs35320474 
Caffeine-Induced Anxiety 
1976C>T 
Alsene et al., 2003 
2592C>T 
rs5751876 Childs et al., 2008; Rogers et al., 2010 
rs2298383 
Childs et al., 2008 
rs4822492 
Amphetamine-Induced Anxiety 
1976C>T 
Hohoff et al., 2005 
2592C>T 
Anxiety-Related Personality 
rs5751862 
Hohoff et al., 2010 rs2298383 
rs3761422 
Table 1. Single-nucleotide polymorphisms (SNPs) in ADORA2A, the gene that encodes the 
adenosine A2A receptor, are involved in a number of anxiety-related psychiatric disorders. 
Perhaps most compelling is the large body of clinical evidence demonstrating that a variety 
of single nucleotide polymorphisms (SNPs) in the A2A receptor gene, ADORA2A, is 
associated with anxiety in several psychiatric disorders and under drug-challenge 
conditions (Table 1). Panic disorder has been associated in different studies with several of 
ADORA2A SNPs including 1083C>T (Hamilton et al., 2004), rs5751876 (Hohoff et al., 2010), 
and 1976C>T (Hamilton et al., 2004). Association of the 1976C>T SNP with panic disorder 
was not replicated in a Chinese population (Lam et al., 2005), although the sample numbers 
were relatively low (>300 total individuals). It is noteworthy that the 1976C>T variant was 
also associated with self-reported anxiety after a moderate dose of orally-administered 
caffeine (150 mg; Alsene et al., 2003), amphetamine (10-20 mg; Hohoff et al., 2005), and 
sympathetic nervous system activation in individuals with blood injury phobia (Hohoff et 
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al., 2009). In addition to panic disorder and agoraphobia, the rs5751876 genetic variant of 
ADORA2A was also associated with autism spectrum disorders (ASD) (Freitag et al., 2010) 
and caffeine-induced anxiety (Childs et al., 2008). Interestingly, a recent study found that 
people with the rs5751876TT genotype, although more susceptible to caffeine-induced 
anxiety, habitually drank more coffee, concluding that tolerance to the anxiogenic effect of 
caffeine occurs regardless of susceptibility (Rogers et al., 2010). Two other variants of the 
A2A receptor gene, rs2298383 and rs3761422, were found to be associated with multiple 
anxiety-related personality scores (Hohoff et al., 2010), with the former also involved in 
caffeine-induced anxiety (Childs et al., 2008), and the latter influencing phenotypic 
variability in ASD symptoms (Freitag et al., 2010). Other variants, rs2236624CC and 
rs35320474 (Freitag et al., 2010), associated more specifically with ASD, while rs4822492 was 
related to caffeine-induced anxiety (Childs et al., 2008), and rs5751862 was related more 
broadly to anxious personality (Hohoff et al., 2010). Although the effect of these SNPs on the 
expression or function of the A2A receptor is not yet known, it is clear that this receptor is 
crucial to the regulation of anxiety. 
3.2 The A1 receptor 
In contrast to the A2A receptor, a role for the A1 receptor has been more difficult to establish. 
Genetic knockout of the A1 receptor appears to argue for this receptor mediating the 
anxiolytic activity of adenosine, while approaches relying solely on pharmacological 
methods have been less clear. Moreover, no studies to date have implicated genetic variants 
of the A1 receptor in anxiety disorders in humans.  
Pharmacological regulation of the A1 receptor has borne mixed results, with some studies 
demonstrating anxiolytic properties of its activation, others showing anxiolysis produced by 
its inhibition, and still others showing no effect of A1 ligands on anxiety measures at all. 
Moreover, the differences in these studies are difficult to reconcile on the basis of drug 
selectivity or dose. For example, one study showed that A1 receptor agonist CCPA was 
anxiolytic in the elevated plus maze and LD box, while A1 receptor antagonists CPT and 
IBMX were anxiogenic in these tests (Florio et al., 1998). Another study showed that the 
anxiogenic effect of A1-selective antagonist DPCPX was unaffected by A1 agonist CPA. Yet 
another study showed the both CPA and CPX (A1 antagonist) decreased the anxiolytic 
activity of ifenprodil (a glutamate NMDA antagonist; Fraser et al., 1996). Likewise, 
antagonism of A1 receptors has been implicated in the actions of magnolia and ziziphus 
extracts, traditional Eastern treatment of mild anxiety and nervousness (Koetter et al., 2009).  
Where pharmacology has failed to illustrate a consistent role for the A1 receptor in anxiety-like 
behavior, genetic methods have yielded a much clearer picture. Deletion of the A1 receptor 
gene in mice results in increased measures of anxiety in several different behavioral assays, 
including decreased exploration in the open-field and hole board, reduced open arm entries 
and time in the elevated plus maze, less time in the light portion of the LD box (Gimenez-Llort 
et al., 2002), and increased wall-hugging in the water maze (Lang et al., 2003). A1 receptor 
knockouts also show a reduction in adenosine-mediated inhibition of glutamate 
neurotransmission and abolishment of theophylline-induced enhancement of glutamatergic 
signaling (Johansson et al., 2001). Other changes in these mice include reduced activity during 
some phases of the LD cycle, and reduced muscle strength and survival (Gimenez-Llort et al., 
2002), indicating a possible role for the A1 receptor in aging-related deficits, despite the normal 
spacial performance by the mice (Lang et al., 2003). Additionally, mice lacking the 
preproenkephalin gene, that show decreased locomotor activity, hyperalgesia, increased 
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anxiety and aggression, have enhanced central A1 receptor-specific DPCPX binding, 
presumably reflecting an attempt to counteract or balance the loss of endogenous opioids 
(Bailey et al., 2004).  These lines of evidence support the notion that the A1 receptor does 
indeed regulate anxiety, and that its activation produces an anxiolytic behavioral response. 
There is also preclinical evidence that the A1 receptor may be involved in anxiety-like 
behavior in stressed animals and rodent models of hyperthyroidism. Rats subjected to a 3-
day stress procedure showed a 15% increase in A1 receptor binding in hypothalamic 
membrane preparations, as well as higher plasma corticosterone (Anderson et al., 1987). 
Thyroid hormones affect the development, function, and expression of A1 receptors and 
regulate the transport of adenosine in the brain (Fideu et al., 1994), a hallmark of 
hyperthyroidism is anxiety. Hyperthyroidism induction was shown to have lasting effects 
on nucleotide hydrolysis (and thus, the availability of adenosine) in the rat brain, with 
young rats showing decreases of 14-52% in the hippocampus and cortex, while older rats 
had increased AMP hydrolysis in the cortex, but lasting decreases in the hippocampus 
(Bruno et al., 2003). Because CPA reduced anxiety-like behavior in hyperthyroid rats (Bruno 
et al., 2006), reduced A1 receptor activation may underlie anxiety in hyperthyroidism. 
3.3 ENT1 
As discussed above, nucleoside transport is one of the most important determinants of 
adenosine levels in the CNS (Dunwiddie, 1985; Burnstock, 2008). Of the several equilibrative 
and concentrative transporters expressed in the brain, ENT1 appears to be central to the 
regulation of anxious states. Some of the first evidence in support of this idea came from a 
study demonstrating that pharmacological inhibition of adenosine uptake by papaverine 
was anxiolytic in the elevated plus maze test (Zangrossi et al., 1992). This study also 
suggested that inhibition of adenosine uptake may be a mechanism of the anxiolytic drug 
carbamazepine, as its actions were inhibited by adenosine receptor antagonist 
aminophylline (Zangrossi et al., 1992). It is noteworthy that multiple studies have also 
pointed to inhibition of ENT1 as a mechanism for benzodiazepine-induced anxiolytic 
activity (discussed later). Recently, we showed that mice lacking ENT1 display decreased 
baseline anxiety levels in the open-field, elevated plus maze, and LD box tests (Chen et al., 
2007). Moreover, decreased anxiety in the open-field and elevated plus maze was replicated 
in C57BL/6J mice after microinjection of the ENT1 inhibitor NBTI (also called NBMPR) into 
the amygdala (Chen et al., 2007). NBTI binding was also upregulated in the brain following 
deletion of the preproenkephalin gene in mice, a manipulation which increases anxiety and 
aggression (Bailey et al., 2004). Increased ENT1 levels were accompanied by increases in A1 
receptor levels in this study, with these changes presumably an adaptive response to the 
loss of opioid peptides (Bailey et al., 2004). One clinical study undertaken to test the effect of 
dipyridamole on anxiety demonstrated no measurable improvement in patients with 
generalized anxiety disorder or panic disorder (Stein et al., 1993), although the sample size 
was extremely low (under 20 patients), and dipyridamole is not a very specific drug, acting 
as an inhibitor of both adenosine uptake and adenosine deaminase. The role of ENT1 and 
other nucleoside transporters in regulating anxiety clearly warrants future investigation. 
4. Adenosine-GABA interactions in anxiety 
Another well-known neurotransmitter system involved in the regulation of anxiety is the 
GABAergic system (Baldwin and File, 1989; Crestani et al., 1999; Kash et al., 1999; Löw et al., 
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2000; Hodge et al., 2002). The relationship between GABAergic and adenosinergic signaling 
is interesting, because there is considerable functional overlap between their actions, such as 
the reduction of neuronal excitability. However, in contrast to the globally inhibitory actions 
of GABA upon neurons in the adult brain, adenosine can act as a permissive factor for 
signaling by other neurotranmitters, excitatory and inhibitory alike. Hence, the actions of 
adenosine on GABAergic signaling are similar to its actions on glutamatergic signaling, and 
whether adenosine dampens or potentiates GABA effects depends upon the expression site 
of adenosine receptors and their differential activation by ever-fluctuating adenosine 
concentrations. Given the implication of both GABA and adenosine signaling in decreasing 
anxiety, it is surprising that little research has focused on how these systems interact in 
anxiety disorders. The benzodiazepine anxiolytics, which potentiate signaling through the 
GABAA receptor, also interact with the adenosinergic system at several levels. These 
interactions represent the main focus of this section. 
4.1 Benzodiazepines and adenosine signaling 
In addition to their potentiation of GABAA receptor-mediated signaling, benzodiazepines 
(BZDs) are known to inhibit adenosine uptake, and several authors have suggested that this 
action may underlie, at least in part, the anxiolytic effect of these agents (Bruns et al., 1983; 
Phillis, 1984; Phillis and O'Regan, 1988). Indeed, diazepam and adenosine share a similar 
physico-chemical structure (Bruns et al., 1983). Inhibition of adenosine uptake by BZDs, 
including diazepam, lorazepam, and flurazepam, has been demonstrated in different 
experimental preparations, including rat brain synaptosomes (Phillis et al., 1980) and guinea 
pig ventricle (Barker and Clanachan, 1982). A study showing that BZDs prevent NBTI 
binding revealed ENT1 as a specific target of these drugs (Hammond et al., 1981). This is 
consistent with the reduced anxiety-like behavior in ENT1 knockout mice (Chen et al., 2007) 
and the anxiolytic action of adenosine uptake inhibitor papaverine (Zangrossi et al., 1992).  
Given their structural similarities with adenosine, it is not surprising that BZDs have also 
been shown to interact with adenosine receptors in some cases. Furthermore, modifications 
in adenosine signaling have been linked to BZD withdrawal responses in animal models. 
Both the A1 and A2 subtypes of adenosine receptors appear to be affected by BZD treatment, 
but most evidence points to the A1 receptor as playing a larger role in BZD action. BZDs did 
not displace chloroadenosine from A1 receptors, indicating that direct action on these 
receptors is not likely responsible for BZD-mediated anxiolytic activity (Williams et al., 
1981). Chronic treatment with mixed A1/A2A receptor antagonists, caffeine or theophylline, 
reduced GABA potentiated flunitrazepam binding to the BZD site on the GABAA receptor 
(Roca et al., 1988). Since this action was blocked by chloroadenosine (Roca et al., 1988), it 
appears that A1 receptor activation is required for the full potentiation of GABAA receptor 
signaling by BZDs. Studies on BZD withdrawal also indicate that A1 receptor-mediated 
responses are integral to the effects of these anxiolytics. For example, administration of 
either caffeine or selective A1 receptor antagonist DPCPX intensified BZD withdrawal in 
mice (Listos et al., 2006). Additionally, A1 receptor agonist CPA was more efficacious in 
attenuating BZD withdrawal signs in mice than A2A receptor agonist CGS (Listos et al., 
2005). Both studies support at least a minor role of A2A receptors in the actions of BZDs, 
which is in agreement with an older study showing displacement of adenosine from A2 
receptors by BZDs in neuroblastoma x glioma hybrid cells (Snell and Snell, 1984). In this 
same study, diazepam facilitated A2-mediated cAMP production, but had no effect on this 
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measure in the absence of adenosine (Snell and Snell, 1984). While the exact contribution of 
A1 and A2 receptors in the effects of BZDs is not known, it appears a role exists for 
endogenous adenosine in the anxiolytic properties of this class of drug. This is consistent 
with the elevated availability of adenosine that results from ENT1 blockade by BZDs 
(discussed previously). Finally, this evidence indicates that BZDs might lose anxiolytic 
efficacy in habitual caffeine or theophylline consumers, and that people withdrawing from 
BZDs should avoid coffee, tea, and cola. 
4.2 Other adenosine-GABA interactions 
Adenosine signaling has also been implicated in the effects of other types of anxiolytic 
compounds that are known to potentiate GABAA receptor-mediated neuronal inhibition. 
Carbamazepine, an anxiolytic and anticonvulsant drug, reduces neuronal excitability in 
several ways, including stabilization of the inactivated state of sodium channels and GABAA 
receptor activation. Evidence for the involvement of adenosine in carbamazepine-mediated 
anxiolytic activity comes from a study showing that nonselective adenosine receptor 
antagonist aminophylline blocked the increase in open-arm time in the elevated plus maze 
in mice (Zangrossi et al., 1992). It is conceivable that adenosine acts as a permissive factor for 
GABAA activation, similar to the manner in which adenosine appears to partially mediate 
BZD action. Another study citing synergism between adenosine and GABAA signaling in 
reducing anxiety demonstrated that the anxiolytic activity of prostaglandin D2 in the 
elevated plus maze test in mice was blocked by both A2A receptor antagonist SCH58261 and 
GABAA receptor antagonist bicuculline (Zhao et al., 2009). The synergism between 
adenosine and GABA in regulating anxiety remains an interesting and potentially important 
future prospect in the field of anxiety disorders. 
5. Regulation of adenosine signaling by caffeine and alcohol 
Caffeine and alcohol are the two most commonly used psychoactive substances in the 
world. Research has revealed that adenosine signaling is central to the anxiety regulating 
effects of these drugs. While people can benefit from many of the effects of adenosine 
receptor antagonism by caffeine, such as increased alertness, improved attention or focus, 
and even amelioration of depressive symptoms (Lara, 2010), sensitivity to caffeine-induced 
anxiogenesis may preclude certain individuals from enjoying coffee, tea, cola, or chocolate. 
On the other hand, moderate doses of alcohol are anxiolytic, and sensitivity to this effect 
may lead a person to abuse alcohol. There is a large body of information indicating that 
several of the CNS depressant effects of alcohol, including anxiolytic activity, are mediated 
by adenosine. In this section, the regulation of adenosine signaling by these substances will 
be discussed, with emphasis on how such action influences anxious behavior. 
5.1 Caffeine 
Much of what is currently known about adenosine signaling in general is based on studies 
using caffeine. Caffeine exerts its stimulant effects on the CNS by inhibiting adenosine A1 
and A2A receptors, as does the related compound theophylline, and other synthetic 
methylxanthine derivatives. Caffeine can also inhibit phosphodiesterases and mobilize 
intracellular calcium, but the doses required for such actions are enormous, and not 
physiologically relevant (Nehlig et al., 1992). High (but physiological) doses of caffeine 
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cause anxiety in most people, low doses go essentially unnoticed, but significant individual 
differences exist in sensitivity to moderate doses of caffeine. Such individual differences in 
response to caffeine have been linked specifically to genetic polymorphisms in the A2A 
receptor gene (ADORA2A), which may affect the expression or function of the receptor. 
Self-reported anxiety after moderate caffeine intake (150 mg, oral) was associated with 
ADORA2A variants 1976C>T and 2592C>T (Alsene et al., 2003). Individuals with the 
ADORA2A SNP rs5751876TT also had greater susceptibility to caffeine-induced 
anxiogenesis (Rogers et al., 2010). A puzzling observation in this study was that these 
genetically susceptible people tended to drink more coffee habitually, and that moderate to 
high habitual consumers of caffeine experienced less caffeine-induced anxiety, irrespective 
of genotype (Rogers et al., 2010). Thus, it appears that the history of caffeine exposure itself 
is a better predictor of whether or not someone will feel anxious when consuming caffeine. 
However, several SNPs in the ADORA2A gene, including those influencing responses to 
caffeine, are also associated with panic disorder, agoraphobia, autism, and amphetamine-
induced anxiety (discussed previously), consistent with an older study showing that the 
majority of patients with agorophobia and panic disorder find caffeine to be anxiogenic 
(Charney et al., 1985). The results of these genome association studies underscore the 
importance of the A2A receptor in several manifestations of anxiety. 
Preclinical studies on the effects of caffeine largely support the clinical observations, 
including the central role of the A2A receptor in caffeine-induced anxiogenesis. Caffeine, 
theophylline, and DPCPX were anxiogenic in the LD box test, with these effects reduced by 
A2 agonist CGS21680, but not by A1 agonist CPA (Imaizumi et al., 1994). Moreover, high-
dose caffeine treatment, both acutely and chronically administered, failed to induce anxiety 
in A2A receptor knockout mice in the elevated plus maze test (El Yacoubi et al., 2000). 
Prenatal caffeine exposure in Sprague-Dawley rats reduced anxiety in the elevated plus 
maze and the LD box, and enhanced responses to A2A receptor agonist CGS21680 (Pan and 
Chen, 2007). Pretreatment with caffeine or theophylline reversed the anxiolytic effect of 
adenosine in the elevated plus maze and elevated zero maze (Kulkarni et al., 2007). 
Interestingly, despite being anxiogenic in Wistar rats in the elevated plus maze, caffeine 
actually increased open arm time after the rats underwent a chronic, unpredictable stress 
procedure (Pechlivanova et al., 2010), a method to model depression in rodents. This 
reduction in anxiety-like behavior by caffeine in the context of depression may be related to 
other evidence suggesting that moderate caffeine intake (< 6 cups/day) was associated with 
less depression and a lower risk of suicide (Lara, 2010). This suggests that different 
mechanisms may underlie the pathogenesis of anxiety and depression, despite their co-
occurrence in many psychiatric diseases, and that both may involve changes in adenosine 
signaling. 
5.2 Alcohol 
Adenosine is known to contribute to many of the intoxicating effects of alcohol, such as its 
ataxic and sedative properties (Ruby et al., 2010; Asatryan et al., 2011). In general, sensitivity 
to the aversive effects of ethanol is inversely correlated with alcohol consumption. Indeed, 
the importance of adenosine signaling in the subjective effects of alcohol has been illustrated 
recently by the tragic deaths of several college students who were drinking the caffeinated 
alcoholic beverage,Four Loko, which has subsequently been taken off the market by the 
FDA. The incredibly high blood alcohol levels achieved by drinkers of Four Loko (0.4%) 
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reflected caffeine’s ability to decrease sensitivity to the stumbling and tiredness associated 
with drinking large quantities of alcohol. Importantly, adenosine also appears to mediate 
some of the reinforcing effects of alcohol, including its well-known ability to reduce feelings 
of anxiety. Increased sensitivity to rewarding or reinforcing effects of ethanol is associated 
with greater drinking.  
Ethanol reinforcement is in part mediated by A2A receptor activation and associated 
intracellular signaling cascades in the nucleus accumbens (Adams et al., 2008), but the exact 
contribution of A2A receptor-mediated signaling to drinking behavior remains unclear. A2A 
receptor knockout mice show hyposensitivity to the intoxicating effects of ethanol and self-
administer more alcohol than do wild-types (Naassila et al., 2002). As discussed previously, 
these mice also display increased basal anxiety, a potential contributing factor to their 
drinking behavior. Despite the counterintuitive observation that A2A null mice showed 
reduced conditioned place preference for ethanol, they demonstrated increased sensitivity 
to the anxiolytic and locomotor stimulating (ie. pleasant) effects of alcohol, which may 
explain their greater ethanol self-administration (Houchi et al., 2008). Furthermore, the A2A 
receptor agonist CGS21680 reduced alcohol consumption and preference in C57BL/6J mice 
(Houchi et al., 2008). Another study showed that A2A receptor antagonist DMPX dose-
dependently decreased lever-pressing for ethanol in an operant chamber, but had no effect 
on anxiety measures in the elevated plus maze or Vogel conflict assessments (Thorsell et al., 
2007). However, yet another study showed that A2A receptor antagonist ZM241385 had no 
effect on the anxiolytic activity of ethanol, suggesting instead that the A1 receptor mediates 
this effect (Prediger et al., 2004). The contradictory results of these studies may reflect 
differences in specificity of the adenosinergic drugs administered, or general differences in 
approach between genetic and pharmacological studies. Alternatively, it may reflect a 
missing factor that affected the balance of adenosine signaling in opposite ways. Whether or 
not polymorphisms in ADORA2A are associated with alcohol intake patterns in humans is 
not yet known, so this is an interesting future prospect. 
The adenosine transporter ENT1 appears to be involved in many aspects of alcohol-related 
behaviors (Choi et al., 2004; Chen et al., 2010; Nam et al., 2010; Nam et al., 2011) and anxiety 
(Chen et al., 2007). Moreover, a recent study showed that a polymorphism in the gene 
encoding ENT1 is associated with alcoholism and depression in women (Gass et al., 2010) 
and alcoholics with a history of withdrawal seizures (Kim et al., 2011). Acute ethanol 
inhibits ENT1, while chronic alcohol treatment leads to decreased ENT1 expression (Short et 
al., 2006; Sharma et al., 2010). This action of ethanol appears to be related to its ability to 
produce anxiolysis, as ENT1 null mice display decreased anxiety-like behavior in the open-
field, elevated plus maze, and LD box (Chen et al., 2007). Microinjection of ENT1-specific 
inhibitor NBTI into the amygdala of C57BL/6J mice similarly reduced anxiety in the open-
field and elevated plus maze tests (Chen et al., 2007). Interestingly, both manipulations 
resulted in increased alcohol consumption and preference, indicating that decreasing 
anxiety (negative reinforcement) does not appear to play a large role in the motivation for 
alcohol in this model. Since ENT1 null mice also show reduced conditioned place aversion 
for ethanol (Chen et al., 2010), their high alcohol drinking may be in part related to a lack of 
“healthy” amounts of anxiety and aversion that would normally prevent them from 
consuming large amounts of ethanol (ie. a greater degree of impulsivity). The data on ENT1 
null mice is consistent with the evidence presented earlier in the chapter suggesting that 
ENT1 inhibition may be a mechanism by which benzodiazepines exert their anxiolytic 
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effects. As both high anxiety and low anxiety are associated with increased alcohol drinking 
behavior in studies of adenosine signaling, perhaps this apparent paradox highlights the 
importance of appropriate degrees of anxiety (and well-balanced adenosine signaling) in 
preventing excessive alcohol intake.  
Abberrant adenosine signaling is also likely related to anxiety responses during ethanol 
withdrawal. Adenosine agonist R-PIA decreased open arm time in the elevated plus maze, 
while antagonist CPT produced partial recovery from ethanol withdrawal-induced anxiety 
(Gatch et al., 1999). CPT itself was anxiolytic in the LD box in rats, but did not reduce their 
ethanol consumption or preference (Gatch et al., 1999). A more recent study showed that 
adenosine and A1 receptor agonist CCPA, at doses that were not normally anxiolytic, 
reduced peak-time ethanol hangover-induced anxiety in the elevated plus maze (Prediger et 
al., 2006). The effect of CCPA was reversed by pretreatment with A1 receptor antagonist 
DPCPX, while A2A receptor agonist DPMA had no effect (Prediger et al., 2006). Differences 
between these studies may reflect the specificity of the adenosine ligands used, or the time 
and intensity of ethanol exposure. 
6. Conclusion 
Adenosine is a ubiquitous CNS neuromodulator that regulates the signaling of major 
neurotransmitter systems involved in mood and emotion. Adenosine and adenosine 
receptor agonists are anxiolytic, while antagonists such as caffeine, are anxiogenic at high 
doses in most people, or at moderate doses in susceptible individuals. The availability of 
adenosine is largely regulated by nucleoside transporters such as ENT1, whose inhibition by 
benzodiazepines and alcohol may underlie their anxiolytic actions. Research also implies 
that adenosine-mediated signaling potentiates activation of the GABAA receptor, another 
target of anxiolytic drugs. Two types of adenosine receptors, the A1 and A2A subtypes, 
appear to contribute differentially to the regulation of anxious states. Both preclinical 
evidence and genome association studies strongly suggest that the A2A receptor plays a 
central role in anxiety-related disorders, including panic disorder with agoraphobia, autism 
spectrum disorder, and anxiogenic responses to stimulants. Multiple lines of evidence 
support that deviation from a relatively narrow range of adenosinergic signaling balance 
may contribute to the development of many psychiatric conditions linked with anxiety, 
including depression and alcoholism.  
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